Beyond the Glycaemic Control of Dapagliflozin : Impact on Arterial Stiffness and Macroangiopathy
González Clemente, José Miguel (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
García-Castillo, María (AstraZeneca (Madrid))
Gorgojo-Martínez, Juan J. (Hospital Universitario Fundación Alcorcón)
Jiménez, Alberto (AstraZeneca (Madrid))
Llorente, Ignacio (Hospital Universitario de Nuestra Señora de la Candelaria)
Matute, Eduardo (AstraZeneca (Madrid))
Tejera, Cristina (Complejo Hospitalario Universitario de Ferrol)
Izarra, Aitziber (AstraZeneca (Madrid))
Lecube, Albert (Institut de Recerca Biomèdica de Lleida)
Universitat Autònoma de Barcelona

Date:	2022
Abstract:	Dapagliflozin is a selective sodium-glucose cotransporter 2 inhibitor (SGLT2i) indicated for the treatment of type 2 diabetes mellitus (T2DM), heart failure with reduced ejection fraction and chronic kidney disease. In all indications, treatment can be initiated in adults with estimated glomerular filtration rate of at least 25 mL/min/1. 73 m 2. As monotherapy or as an additive therapy, dapagliflozin has been shown to promote better glycaemic control, associated with a reduction in body weight and blood pressure in a wide range of patients. In addition, dapagliflozin has a positive impact on arterial stiffness, helps to control the lipid profile and contributes to a reduced risk of cardiovascular complications. This article reviews the current scientific evidence on the role of dapagliflozin in cardiovascular risk factors including arterial stiffness, cardiovascular disease and heart failure in patients with T2DM, with the aim of helping to translate this evidence into clinical practice. The underuse of SGLT2i in actual clinical practice is also discussed.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Cardiovascular diseases ; Dapagliflozin ; Heart failure ; Sodium-glucose transporter 2 inhibitors ; Therapeutic inertia ; Type 2 diabetes mellitus
Published in:	Diabetes Therapy, Vol. 13 (june 2022) , p. 1281-1298, ISSN 1869-6961

DOI: 10.1007/s13300-022-01280-6
PMID: 35687260

18 p, 410.0 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Parc Taulí Research and Innovation Institute (I3PT
Articles > Research articles
Articles > Published articles